Compare Stocks → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BYSINASDAQ:CRBPNASDAQ:LXRXNASDAQ:MISTNASDAQ:XENE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$2.29+8.5%$2.37$0.65▼$4.00$89.13M0.14188,369 shs112,151 shsCRBPCorbus Pharmaceuticals$37.74+0.1%$35.88$3.03▼$49.87$396.65M2.45795,268 shs500,504 shsLXRXLexicon Pharmaceuticals$1.61-5.8%$2.31$0.92▼$3.79$421.07M1.274.45 million shs3.51 million shsMISTMilestone Pharmaceuticals$1.70+4.3%$1.67$1.33▼$4.49$90.36M1.77311,937 shs90,452 shsXENEXenon Pharmaceuticals$41.09+2.7%$44.47$27.99▼$50.99$3.10B1.15401,870 shs323,512 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring+10.47%+19.89%-32.37%+134.97%+95.37%CRBPCorbus Pharmaceuticals-3.92%-11.75%+7.90%+416.44%+326.47%LXRXLexicon Pharmaceuticals+3.64%-8.56%-24.34%+6.87%-31.33%MISTMilestone Pharmaceuticals-0.61%-7.12%-6.32%+5.84%-59.45%XENEXenon Pharmaceuticals+0.33%-3.15%-9.07%-11.19%+1.57%Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBYSIBeyondSpring0.0033 of 5 stars0.00.00.00.00.02.50.0CRBPCorbus Pharmaceuticals4.4877 of 5 stars3.53.00.04.72.93.30.6LXRXLexicon Pharmaceuticals0.9876 of 5 stars3.01.00.00.01.91.70.6MISTMilestone Pharmaceuticals2.3211 of 5 stars3.43.00.00.03.22.50.0XENEXenon Pharmaceuticals1.7297 of 5 stars3.52.00.00.02.22.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpringN/AN/A$1.25-45.41% DownsideCRBPCorbus Pharmaceuticals3.00Buy$52.0037.78% UpsideLXRXLexicon Pharmaceuticals2.00Hold$5.00210.56% UpsideMISTMilestone Pharmaceuticals2.75Moderate Buy$10.75532.35% UpsideXENEXenon Pharmaceuticals3.00Buy$59.4444.67% UpsideCurrent Analyst RatingsLatest MIST, BYSI, CRBP, XENE, and LXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold4/12/2024XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$62.004/11/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold4/10/2024XENEXenon PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.003/22/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.003/13/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.003/6/2024CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.00 ➝ $46.003/5/2024MISTMilestone PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$6.00 ➝ $5.003/1/2024XENEXenon PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $55.003/1/2024XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$46.00 ➝ $51.003/1/2024XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $62.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpring$1.35M66.02N/AN/A($0.36) per share-6.36CRBPCorbus Pharmaceuticals$880K450.74N/AN/A($1.56) per share-24.19LXRXLexicon Pharmaceuticals$1.20M329.27N/AN/A$0.38 per share4.24MISTMilestone Pharmaceuticals$1M90.36N/AN/A$0.50 per share3.40XENEXenon Pharmaceuticals$9.43M328.68N/AN/A$14.18 per share2.90Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$33.28MN/A0.00∞N/AN/AN/AN/AN/ACRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%5/14/2024 (Estimated)LXRXLexicon Pharmaceuticals-$177.12M-$0.80N/AN/AN/A-14,573.20%-138.54%-71.29%5/7/2024 (Estimated)MISTMilestone Pharmaceuticals-$59.69M-$1.39N/AN/AN/AN/A-170.99%-64.45%5/9/2024 (Estimated)XENEXenon Pharmaceuticals-$182.39M-$2.72N/AN/AN/AN/A-25.18%-23.99%5/14/2024 (Estimated)Latest MIST, BYSI, CRBP, XENE, and LXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023MISTMilestone Pharmaceuticals-$0.30-$0.32-$0.02-$0.32N/AN/A3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/A3/11/2024Q4 2023LXRXLexicon Pharmaceuticals-$0.23-$0.20+$0.03-$0.20$0.68 million$0.70 million2/29/2024Q4 2023XENEXenon Pharmaceuticals-$0.76-$0.64+$0.12-$0.64$2.30 millionN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/AN/AN/ACRBPCorbus PharmaceuticalsN/A0.740.74LXRXLexicon Pharmaceuticals1.075.605.58MISTMilestone Pharmaceuticals2.9710.1110.11XENEXenon PharmaceuticalsN/A23.6523.65OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%CRBPCorbus Pharmaceuticals64.64%LXRXLexicon Pharmaceuticals74.70%MISTMilestone Pharmaceuticals86.18%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%CRBPCorbus Pharmaceuticals4.00%LXRXLexicon Pharmaceuticals6.80%MISTMilestone Pharmaceuticals10.40%XENEXenon Pharmaceuticals5.43%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring7338.92 million27.52 millionOptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableLXRXLexicon Pharmaceuticals285246.24 million235.16 millionOptionableMISTMilestone Pharmaceuticals4753.15 million47.62 millionOptionableXENEXenon Pharmaceuticals25175.43 million71.34 millionOptionableMIST, BYSI, CRBP, XENE, and LXRX HeadlinesSourceHeadlineFederated Hermes Inc. Invests $15.96 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 23 at 5:35 AMInvestors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)americanbankingnews.com - April 18 at 3:04 AMXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 16 at 8:30 AMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Analystsamericanbankingnews.com - April 16 at 2:34 AMXenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Needham & Company LLCamericanbankingnews.com - April 14 at 3:36 AMNeedham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)marketbeat.com - April 12 at 8:14 AMXenon Pharmaceuticals Inc (XENE)investing.com - April 10 at 12:10 PMXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferenceglobenewswire.com - April 10 at 8:30 AMXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 4 at 4:01 PMSG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 2 at 4:18 AMAssenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 1 at 4:43 AMXenon Pharmaceuticals Incmoney.usnews.com - March 21 at 10:13 AMXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - March 19 at 8:26 AMXENE Apr 2024 47.500 putfinance.yahoo.com - March 16 at 1:48 PMXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Daysglobenewswire.com - March 12 at 4:01 PMInsider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of Stockinsidertrades.com - March 11 at 6:41 AMInsider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...finance.yahoo.com - March 9 at 12:06 AMXenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024globenewswire.com - March 5 at 4:01 PMBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progressmarkets.businessinsider.com - March 5 at 10:33 AMXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 2 at 2:52 PMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 2 at 9:52 AMXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 1 at 2:30 PMXenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focuszacks.com - March 1 at 9:36 AMBuy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in Neurosciencemarkets.businessinsider.com - March 1 at 9:23 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideASML Fires Warning Shot For Tech InvestorsApril 17, 2024 9:05 AMView ASML Fires Warning Shot For Tech InvestorsAll Headlines Company DescriptionsBeyondSpringNASDAQ:BYSIBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Corbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Milestone PharmaceuticalsNASDAQ:MISTMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Xenon PharmaceuticalsNASDAQ:XENEXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.